Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial
David S. Small(Eli Lilly (United States)), Ronan P. Kelly(Eli Lilly (Singapore)), Mei Teng Loh(Clinical Nutrition Research Centre), Christopher D. Payne(Eli Lilly (United States)), Eunice Yuen(Eli Lilly (United Kingdom)), Daniel E. Salazar(Daiichi Sankyo (United States)), Fanni Natanegara(Eli Lilly (United States)), Ying G. Li(Eli Lilly (United States)), D. Richard Lachno(Alzheimer's Association), Lan Ni(Inner Mongolia University of Technology), Nagy A. Farid(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Prajakti A. Kothare(Eli Lilly (United States)), Molly Tomlin(Eli Lilly (United States))
Cited by 47
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617